LAVAL, QC, June 18 /CNW/ - Health Canada has approved Eloxatin(R)
(oxaliplatin for injection) in combination with 5-fluorouracil (5-FU) and
leucovorin (LV) (FOLFOX4) for use in first and second-line treatment of
metastatic colorectal cancer. Clinical studies show that Eloxatin(R) in
combination with 5-FU and LV (FOLFOX4) can prolong survival, shrink tumours
and delay the progression of disease in patients with metastatic colorectal
cancer.(1) In Canada, colorectal cancer is the second-leading cause of death
from cancer.(2) Close to 50 per cent of patients diagnosed with colorectal
cancer go on to develop metastatic colorectal cancer.(3)
